Pulmatrix, Inc.
No SEC Form 4 filings for $PULM in the last 30 days.
See all $PULM insider activity →Pulmatrix, Inc. (PULM) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Item 5.07 Submission of Matters to a Vote of Security Holders In connection with the Merger, Pulmatrix held a special meeting in lieu of the annual meeting of Pulmatrix stockholders on October 26, 2026, at 8:30 a.m. Eastern Time (the “Special Meeting”), at which the Pulmatrix sto
Pulmatrix (Nasdaq: PULM) reported 2Q 2026 results and updated investors on its proposed merger with privately held Eos SENOLYTIX. Pulmatrix filed an S-4 and said the deal is expected to close in 3Q 2026. It raised $1.0 million via a private placement. Cash was $2.2 million at June 30, 2026.
Pulmatrix, Inc. (PULM) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Pulmatrix Announces Second Quarter 2026 Financial Results and Progress on Merger Form S-4 filed related to the announced merger agreement with Eos SENOLYTIX Framingham, Mass., August 13, 2026 – Pulmatrix, Inc. (“Pulmatrix” or the “Company”) (Nasdaq: PULM), a biopharm
Over the past 7 days, AlphAI's AI scored 1 news story mentioning PULM (Pulmatrix, Inc.). Coverage has been balanced: 0 bullish, 1 neutral, and 0 bearish.
Recent PULM coverage spans financial news, corporate actions and mergers & acquisitions.
The approvals may lead to dilution and share structure changes, creating short‑term pressure on the stock.
Near-term trading focus is merger execution risk plus cash runway, with additional read-through from Q2 cost and liquidity disclosures.
Near-term trading focus is merger execution risk plus cash runway, while clinical programs are paused pending monetization/licensing.
The announced merger between Pulmatrix and Eos SENOLYTIX is a significant development in the biotech sector, particularly in anti-aging therapeutics. The deal could positively influence PULM's stock, reflecting investor optimism about the company's growth prospects in this niche.
Pulmatrix (PULM) reported a 100% revenue decline in Q2 2025, indicating severe operational challenges or strategic setbacks.
AlphAI scores every news story that mentions PULM with an AI model for sentiment and relevance, and aggregates insider trades from Pulmatrix, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Pulmatrix, Inc. (PULM) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Item 5.07 Submission of Matters to a Vote of Security Holders In connection with the Merger, Pulmatrix held a special meeting in lieu of the annual meeting of Pulmatrix stockholders on October 26, 2026, at 8:30 a.m. Eastern Time (the “Special Meeting”), at which the Pulmatrix sto
2 min readPulmatrix (Nasdaq: PULM) reported 2Q 2026 results and updated investors on its proposed merger with privately held Eos SENOLYTIX. Pulmatrix filed an S-4 and said the deal is expected to close in 3Q 2026. It raised $1.0 million via a private placement. Cash was $2.2 million at June 30, 2026.
6 min readPulmatrix, Inc. (PULM) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Pulmatrix Announces Second Quarter 2026 Financial Results and Progress on Merger Form S-4 filed related to the announced merger agreement with Eos SENOLYTIX Framingham, Mass., August 13, 2026 – Pulmatrix, Inc. (“Pulmatrix” or the “Company”) (Nasdaq: PULM), a biopharm
5 min readPulmatrix, Inc. has announced a definitive merger agreement to acquire Eos SENOLYTIX, Inc. in a $19 million deal. The combined entity will operate as Eos SENOLYTIX, Inc., trading on Nasdaq under "EOSX," and will focus on developing peptide therapies for aging-related diseases, particularly sarcopenia, through Eos’s MitoXcel platform. The transaction, which includes concurrent private financings, is subject to stockholder approval and regulatory requirements and is expected to close in mid-2026.
4 min readPulmatrix ( NASDAQ:PULM ) , a biotechnology company known for its dry powder inhalation delivery platform iSPERSE™, released its second quarter results on August 6, 2025, covering the quarter that ended June 30, 2025. Pulmatrix reported zero revenue for the period ended June 30, 2025.
2 min read
